Blood test may let some lymphoma patients skip late chemo rounds

This study is testing whether a new blood test (PhasED-seq) can detect leftover cancer DNA in real time during standard chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL). For patients whose blood shows no cancer DNA halfway through treatment, doctors will shorten the remaining chemo from 6 to 4 cycles. The goal is to see if this approach is feasible and safe, potentially sparing patients from extra side effects. The trial enrolls 40 adults with stage II–IV DLBCL and uses no experimental drugs—only the test itself is investigational.